PM
JANX icon

Prosight Management’s Janux Therapeutics JANX Stock Holding History

Prosight Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.4M Buy
3,804,481
+254,481
+7% +$3.69M 10.07% 2
2026
Q1 		$49.3M Buy
3,550,000
+1,157,477
+48% +$15.9M 8.09% 3
2025
Q4 		$33M Buy
2,392,523
+1,527,173
+176% +$35.9M 6.82% 3
2025
Q3 		$21.1M Buy
865,350
+11,446
+1% +$279K 4.93% 6
2025
Q2 		$19.7M Buy
853,904
+164,003
+24% +$4.32M 4.81% 8
2025
Q1 		$18.6M Buy
689,901
+360,133
+109% +$13.6M 6.12% 4
2024
Q4 		$17.7M Buy
329,768
+124,768
+61% +$6.6M 4.88% 10
2024
Q3 		$9.31M Buy
+205,000
New +$8.92M 2.29% 19

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Prosight Management's JANX Position: Q2 2026 in Review

Prosight Management increased its Janux Therapeutics (JANX) stake by 7.2% in Q2 2026, buying an estimated $3.69M and bringing the position to 3,804,481 shares worth $58.4M. The position accounts for 10.07% of the portfolio, ranked #2.

Prosight Management first reported a position in JANX in Q3 2024 and has held it in 8 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Prosight Management held 3,804,481 shares of Janux Therapeutics worth $58.4M as of Q2 2026.
  • Prosight Management bought 254,481 Janux Therapeutics shares in Q2 2026, an estimated $3.69M.
  • Janux Therapeutics made up 10.07% of Prosight Management's portfolio in Q2 2026, its #2 holding.
  • Prosight Management first reported a position in Janux Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.